MA32621B1 - Traitement de maladie auto-immune et inflammatoire - Google Patents

Traitement de maladie auto-immune et inflammatoire

Info

Publication number
MA32621B1
MA32621B1 MA33682A MA33682A MA32621B1 MA 32621 B1 MA32621 B1 MA 32621B1 MA 33682 A MA33682 A MA 33682A MA 33682 A MA33682 A MA 33682A MA 32621 B1 MA32621 B1 MA 32621B1
Authority
MA
Morocco
Prior art keywords
autoimmune
treatment
inflammatory disease
biological activity
multiple sclerosis
Prior art date
Application number
MA33682A
Other languages
Arabic (ar)
English (en)
Inventor
Stewart Leung
Lixin Li
Xuebin Liu
Hongtao Lu
Ping Tsui
Jingwu Zang
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA32621B1 publication Critical patent/MA32621B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouveaux procédés de traitement de la sclérose en plaques et d'autres maladies auto-immunes ou troubles inflammatoires, et des antagonistes, comprenant des protéines de liaison isolées pour une utilisation dans les nouveaux procédés. La présente invention concerne en outre un procédé de traitement de la sclérose en plaques comprenant la neutralisation de l'activité biologique de il-7 par liaison à cd127 ou il-7. Les protéines de liaison isolées peuvent également neutraliser l'activité biologique de tslp.
MA33682A 2008-08-08 2011-03-08 Traitement de maladie auto-immune et inflammatoire MA32621B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8729408P 2008-08-08 2008-08-08
US16980109P 2009-04-16 2009-04-16
US21862709P 2009-06-19 2009-06-19
PCT/US2009/053136 WO2010017468A1 (fr) 2008-08-08 2009-08-07 Traitement de maladie auto-immune et inflammatoire

Publications (1)

Publication Number Publication Date
MA32621B1 true MA32621B1 (fr) 2011-09-01

Family

ID=41382165

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33682A MA32621B1 (fr) 2008-08-08 2011-03-08 Traitement de maladie auto-immune et inflammatoire

Country Status (23)

Country Link
US (2) US20110287000A1 (fr)
EP (1) EP2318442A1 (fr)
JP (1) JP2011530533A (fr)
KR (1) KR20110044777A (fr)
CN (1) CN102177179A (fr)
AR (1) AR072985A1 (fr)
AU (1) AU2009279471A1 (fr)
BR (1) BRPI0916945A2 (fr)
CA (1) CA2733432A1 (fr)
CL (1) CL2011000269A1 (fr)
CO (1) CO6341640A2 (fr)
CR (1) CR20110118A (fr)
DO (1) DOP2011000041A (fr)
EA (1) EA201100150A1 (fr)
IL (1) IL211034A0 (fr)
MA (1) MA32621B1 (fr)
MX (1) MX2011001477A (fr)
NZ (1) NZ590994A (fr)
PE (1) PE20110382A1 (fr)
TW (1) TW201018482A (fr)
UY (1) UY32038A (fr)
WO (1) WO2010017468A1 (fr)
ZA (1) ZA201100974B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8171134B2 (en) * 2009-03-18 2012-05-01 At&T Intellectual Property I, L.P. Methods and apparatus to characterize and predict network health status
KR20130028055A (ko) * 2010-01-28 2013-03-18 글락소 그룹 리미티드 Ｃｄ １２７ 결합 단백질
US20130046015A1 (en) * 2010-02-11 2013-02-21 Robert C. Axtell Therapeutic Inhibition of Granulocyte Function in Demyelinating Disease
AU2014201648B2 (en) * 2010-02-24 2016-05-12 Rinat Neuroscience Corp. Antagonist anti-il-7 receptor antibodies and methods
AR080291A1 (es) * 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
WO2011152503A1 (fr) * 2010-06-02 2011-12-08 大日本住友製薬株式会社 Médicament de traitement pour des maladies auto-immunes et des maladies allergiques
WO2012021165A2 (fr) * 2010-08-10 2012-02-16 The Scripps Research Institute Procédés et compositions pour traiter des désordres associés à un système immunitaire hyperactif
CA2858350A1 (fr) 2011-01-14 2013-07-19 The Regents Of The University Of California Anticorps therapeutiques contre la proteine ror-1 et leurs methodes d'utilisation
EP2583980A1 (fr) 2011-10-19 2013-04-24 Effimune Anticorps dirigés contre la chaîne alpha du récepteur IL7, leur utilisation pour la préparation de candidats médicaments
FR2988479B1 (fr) * 2012-03-23 2014-12-19 Hospices Civils Lyon Procede de determination de la susceptibilite aux infections nosocomiales
ES2897635T3 (es) * 2014-04-29 2022-03-02 Bio Cancer Treat International Ltd Métodos y composiciones para modular el sistema inmunológico con la arginasa I
EP2955196A1 (fr) 2014-06-10 2015-12-16 Effimune Anticorps dirigés contre CD127
WO2016044189A1 (fr) * 2014-09-15 2016-03-24 Genentech, Inc. Méthodes de traitement du cancer faisant appel à un antagoniste se liant à l'axe pd-1 et à des antagonistes se liant à l'il-17
KR20170065662A (ko) 2014-10-18 2017-06-13 화이자 인코포레이티드 항-il-7r 항체 조성물
EP3268032A1 (fr) * 2015-03-11 2018-01-17 GlaxoSmithKline Intellectual Property Development Limited Protéines de liaison à la tslp
WO2017055966A1 (fr) 2015-10-01 2017-04-06 Pfizer Inc. Compositions d'anticorps à faible viscosité
CA2997809A1 (fr) 2015-10-07 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps specifiques d'il-7r-alpha pour le traitement la leucemie lymphoblastique aigue
KR102819051B1 (ko) 2016-02-29 2025-06-12 오제 이뮈노테라프틱스 Ｉｌ７ 수용체 세포외 도메인의 알파 쇄에 대해 지시된 비-길항성 항체 및 암 치료에 있어서 이의 용도
US11098128B2 (en) * 2016-12-09 2021-08-24 Ose Immunotherapeutics Antibodies and polypeptides directed against CD127
JP7330896B2 (ja) 2017-04-12 2023-08-22 アムジェン インコーポレイテッド 抗ｔｓｌｐ抗体による喘息治療
EP3914622A1 (fr) * 2019-01-22 2021-12-01 Bristol-Myers Squibb Company Anticorps contre la sous-unité alpha d'un l'il-7r et leurs utilisations
CN115028723B (zh) * 2019-03-07 2023-08-29 瑞阳(苏州)生物科技有限公司 人IL-1β蛋白结合分子及其编码基因和应用
RS66646B1 (sr) 2019-10-28 2025-04-30 Medimmune Ltd Formulacije suvog praška vezujućih antitela za timusni stromalni limfopoetin (tslp) i postupci njihove upotrebe
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
PE20230112A1 (es) 2020-02-13 2023-01-27 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de tratamiento de una enfermedad inflamatoria
EP4103605A1 (fr) 2020-02-13 2022-12-21 Amgen Inc. Traitement de la dermatite atopique avec un anticorps anti-tslp
PH12022552132A1 (en) 2020-02-18 2024-01-29 Amgen Inc Formulations of human anti-tslp antibodies and methods of using the same
CA3199648A1 (fr) 2020-12-02 2022-06-09 Gerben BOUMA Proteines de liaison a il-7 et leur utilisation en therapie medicale
WO2023227641A1 (fr) 2022-05-27 2023-11-30 Glaxosmithkline Intellectual Property Development Limited Utilisation de protéines de liaison au tnf-alpha et de protéines de liaison à l'il-7 dans un traitement médical
TW202448501A (zh) 2023-02-02 2024-12-16 美商麥迪紐有限責任公司 用抗ｔｓｌｐ抗體治療慢性鼻竇炎
EP4455308A1 (fr) 2023-04-24 2024-10-30 Les Laboratoires Servier Signatures géniques il-7r
KR20260021593A (ko) * 2023-06-07 2026-02-13 에프비디 바이올로직스 리미티드 조작된 il-7 변이체 및 이의 사용 방법
WO2026062296A1 (fr) * 2024-09-23 2026-03-26 Ose Immunotherapeutics Thérapie par antagonisation d'l-7 ou cd127, et il-12, il-23, il-12r ou il-23r

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194375A (en) * 1989-06-15 1993-03-16 Immunex Corporation Dna encoding interleukin-7 receptors and methods of use
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994028160A1 (fr) * 1993-06-01 1994-12-08 Toray Industries, Inc. Anticorps monoclonal, procede de production, et utilisation
US20050054054A1 (en) * 2002-11-12 2005-03-10 Foss Francine M. Interleukin-7 molecules with altered biological properties
WO2005123774A2 (fr) * 2004-06-15 2005-12-29 Erol Fikrig Anticorps de polypeptides du virus du nil occidental
WO2006052660A2 (fr) * 2004-11-04 2006-05-18 Childrens Hospital Los Angeles Research Institute Blocage du recepteur il-7 pour supprimer l'immunite
EP2322553A3 (fr) * 2005-02-14 2011-11-16 Wyeth LLC Anticorps de l'interleukine-17F et d'autres antagonistes de signalisation de l'IL-17F et leurs utilisations correspondantes
CA2513350A1 (fr) * 2005-03-02 2006-09-02 Sydney West Area Health Service Traitement contre la sclerose en plaques
GB2434578A (en) * 2006-01-26 2007-08-01 Univ Basel Transgenic animals

Also Published As

Publication number Publication date
AU2009279471A1 (en) 2010-02-11
CN102177179A (zh) 2011-09-07
ZA201100974B (en) 2012-10-31
DOP2011000041A (es) 2011-02-28
BRPI0916945A2 (pt) 2015-11-24
WO2010017468A1 (fr) 2010-02-11
EA201100150A1 (ru) 2011-10-31
NZ590994A (en) 2012-09-28
CO6341640A2 (es) 2011-11-21
KR20110044777A (ko) 2011-04-29
US20100040616A1 (en) 2010-02-18
AR072985A1 (es) 2010-10-06
MX2011001477A (es) 2011-03-25
JP2011530533A (ja) 2011-12-22
UY32038A (es) 2010-03-26
CL2011000269A1 (es) 2012-07-20
CR20110118A (es) 2011-07-28
IL211034A0 (en) 2011-04-28
CA2733432A1 (fr) 2010-02-11
EP2318442A1 (fr) 2011-05-11
PE20110382A1 (es) 2011-06-27
US20110287000A1 (en) 2011-11-24
TW201018482A (en) 2010-05-16

Similar Documents

Publication Publication Date Title
Xu et al. Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain
CO6341640A2 (es) \\\"tratamiento de enfermedad autoinmunitaria e inflamatoria\\\"
MA34053B1 (fr) Polypeptides agonistes de liaison à dr5
MY164376A (en) Phosphospecific antibodies recognizing tau
MA33717B1 (fr) Immunoconjugués ciblés
MA34738B1 (fr) Neutralisation d'anticorps anti-ccl20
MA30962B1 (fr) Anticorps antifacteurs d'humanisés et leurs utilisations.
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
MA29836B1 (fr) Proteines de fusion avec l'albumine
MA32300B1 (fr) Anticorps anti-facteur d humanises et utilisations de ceux-ci
DE60224879D1 (de) Verwendung von dpiv-inhibitoren als therapeutika für krankhafte neurologische zustände
MY171300A (en) Pharmaceutical composition
MX2010001111A (es) Mutantes mcp-1 que antagonizan glicosaminoglicano y metodos para utilizar los mismos.
MX2009005849A (es) Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
WO2005112981A3 (fr) Compositions et methodes permettant de stimuler ou de renforcer l'osteoformation et l'autorenouvellement des cellules
EP2438962A3 (fr) Polynucléotides et séquences de polypeptides impliqués dans le procédé de remodelage des os
BRPI0506890A (pt) derivado de arila diazabicìclica, composição farmacêutica, uso de um derivado de arila diazabicìclica, e, método de tratamento, prevenção ou alìvio de uma doença, distúrbio ou condição de um corpo de animal vivo
EP1566387A3 (fr) Gènes impliqués dans la régulation de l'angiogenese, préparations pharmaceutiques les contenant et leurs applications
MA28969B1 (fr) Aptameres de liaison a la famille des cytokines de l'il-12 humaine et leur utilisation comme agents therapeutiques de maladies auto-immunes
MY149448A (en) Interleukin-21 receptor binding proteins
Teng et al. Immunotherapies for Parkinson’s disease: progression of clinical development
MA33199B1 (fr) Compositions de vaccin et procédés pour le traitement de la mucormycose et d'autres maladies fongiques
WO2004050907A3 (fr) Technique de determination de predisposition a une manifestation de maladies associees au systeme immunitaire
EP2046394A4 (fr) Utilisation de séquences d'acide nucléique pour le traitement de maladies neurologiques et psychiatriques, vecteurs et compositions
ATE517629T1 (de) Verwendung eines proteins der crmp familie zur behandlung von krankheiten des immunsystems